Αποτελέσματα Αναζήτησης
DESCRIPTION. ORTHO EVRA® is a combination transdermal contraceptive patch with a contact surface area of 20 cm2. It contains 6.00 mg norelgestromin (NGMN) and 0.75 mg ethinyl estradiol (EE).
ORTHO EVRA® is a combination transdermal contraceptive patch with a contact surface area of 20 cm 2 .It contains 6.00 mg norelgestromin and 0.75 mg ethinyl estradiol (EE),and releases 150 micrograms of norelgestromin and 20 micrograms of EE to the bloodstream per 24 hours.
PRESCRIBING INFORMATION. ACTIVE INGREDIENT(S): Norelgestromin (NGMN) and ethinyl estradiol (EE). o Summary of Product Characteristics (SmPC) before pre. embolism (VTE), and how the risk of VTE with EVRA. compares with other CHCs (see contraindications and special warn. Adults: Transdermal use. One patc.
SUMMARY OF PRODUCT CHARACTERISTICS. 1. NAME OF THE MEDICINAL PRODUCT. EVRA 203 micrograms/24 hours + 33.9 micrograms/24 hours transdermal patch. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION. Each 20 cm2 transdermal patch contains 6 mg norelgestromin (NGMN) and 600 micrograms ethinyl estradiol (EE).
ORTHO EVRATM is a combination transdermal contraceptive patch with a contact surface area of 20 cm2. It contains 6.00 mg norelgestromin and 0.75 mg ethinyl estradiol (EE), and releases 150 micrograms of norelgestromin and 20 micrograms of EE to the bloodstream per 24 hours.
ORTHO EVRA® [odds ratio 0.9 (95% CI 0.5 – 1.6)]30 (see WARNINGS AND PRECAUTIONS – General, Updated Epidemiologic Data). Prescribers are advised to carefully assess a patient’s baseline and cumulative risk of thromboembolism before prescribing hormonal contraceptives, including EVRA®. Obesity
The EVRA (norelgestromin and ethinyl estradiol) transdermal system, with a contact surface area of 20 cm2, is a thin, matrix-type transdermal system consisting of three layers. Each transdermal system contains 6.0 mg norelgestromin and 0.60 mg ethinyl estradiol (EE).
